{
    "clinical_study": {
        "@rank": "124613", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver\n      cancer-killing substances to them without harming normal cells.\n\n      PURPOSE: Phase III trial to determine the effectiveness of monoclonal antibody therapy in\n      treating patients who have relapsed or refractory non-Hodgkin's lymphoma."
        }, 
        "brief_title": "Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the efficacy and safety of iodine I 131 monoclonal antibody anti-B1\n      in patients with relapsed or refractory, low grade or transformed low grade B-cell\n      non-Hodgkin's lymphoma.\n\n      OUTLINE: On day 1, patients receive unlabeled monoclonal antibody anti-B1 (MOAB anti-B1) IV\n      over 1 hour followed by a tracer dose of iodine I 131 MOAB anti-B1 IV over 30 minutes to\n      determine biodistribution and a therapeutic dose of iodine I 131 MOAB anti-B1. Patients\n      receive unlabeled MOAB anti-B1 IV over 1 hour followed by a therapeutic dose of iodine I 131\n      MOAB anti-B1 IV over 30 minutes on day 8. Patients are followed at weeks 13 and 25 and then\n      every 6 months for up to 2 years.\n\n      PROJECTED ACCRUAL: Expanded Access Trial, no maximum accrual"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically proven relapsed or refractory, low grade or\n        transformed low grade B-cell non-Hodgkin's lymphoma including the following: Small\n        lymphocytic Follicular small cleaved cell Follicular mixed small cleaved and large cell\n        (less than 50% large cell component) Tumor must be positive for CD20 antigen Relapse or\n        disease progression following at least 1 chemotherapy regimen or failure to achieve an\n        objective response (complete or partial response) on prior chemotherapy regimen No disease\n        progression, within 1 year of irradiation, arising in a field previously irradiated with\n        more than 3500 cGy Mean of no greater than 25% intratrabecular marrow space involved with\n        lymphoma on bilateral iliac crest bone marrow biopsy A new classification scheme for adult\n        non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of \"indolent\" or\n        \"aggressive\" lymphoma will replace the former terminology of \"low\", \"intermediate\", or\n        \"high\" grade lymphoma. However, this protocol uses the former terminology.\n\n        PATIENT CHARACTERISTICS: Age: 19 and over Performance status: Karnofsky 60-100% Life\n        expectancy: At least 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3\n        Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of\n        normal (ULN) AST less than 5 times ULN Renal: Creatinine less than 1.5 times ULN No active\n        obstructive hydronephrosis Cardiovascular: No New York Heart Association class III or IV\n        heart disease Other: No active infection requiring IV antibiotics No other concurrent\n        illness that would preclude evaluation No prior malignancy within the past 5 years except\n        adequately treated skin cancer, carcinoma in situ of the cervix, or lymphoma HIV negative\n        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n        contraception during and for 6 months after study No prior allergic reaction to iodine\n        other than IV iodine containing contrast materials Human antimouse antibody negative\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy or\n        cytokine treatment and recovered No prior hematologic stem cell transplantation\n        Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy (at\n        least 6 weeks since prior nitrosoureas) and recovered Endocrine therapy: Not specified\n        Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy and\n        recovered No prior radioimmunotherapy Surgery: Not specified Other: No concurrent IV\n        antibiotics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 7, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004874", 
            "org_study_id": "259-98", 
            "secondary_id": [
                "P30CA036727", 
                "UNMC-259-98", 
                "COULTER-CP-98-020"
            ]
        }, 
        "intervention": {
            "description": "Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit.  An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.", 
            "intervention_name": "tositumomab and iodine I 131 tositumomab", 
            "intervention_type": "Radiation", 
            "other_name": "Iodine-131 Anti-B1 Antibody"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal", 
                "Iodine", 
                "Cadexomer iodine", 
                "Iodine-131 anti-B1 antibody"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "recurrent grade 1 follicular lymphoma", 
            "recurrent grade 2 follicular lymphoma", 
            "recurrent small lymphocytic lymphoma"
        ], 
        "lastchanged_date": "April 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UNMC-259-98"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Omaha", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68198-3330"
                }, 
                "name": "University of Nebraska Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma", 
        "overall_official": {
            "affiliation": "University of Nebraska", 
            "last_name": "Julie M. Vose, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this stud is to make Iodin-131 Anti-B1 Antibody more broadly available to patients", 
            "measure": "Expanded Access", 
            "safety_issue": "No", 
            "time_frame": "Study completion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004874"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary endpoints of the study will be to obtain additional information on the safety of Iodine-131 Anti-B1 Antibody", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Study completion"
            }, 
            {
                "description": "Secondary endpoints of the study will be to obtain additional information on the efficacy of Iodine-131 Anti-B1 Antibody", 
                "measure": "efficacy", 
                "safety_issue": "No", 
                "time_frame": "study completion"
            }
        ], 
        "source": "University of Nebraska", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Coulter Pharmaceuticals, Inc", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Nebraska", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 1998", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013", 
        "why_stopped": "lack of FDA approval"
    }, 
    "geocoordinates": {
        "University of Nebraska Medical Center": "41.252 -95.998"
    }
}